nodes	percent_of_prediction	percent_of_DWPC	metapath
Trametinib—MAP2K1—neck—pharynx cancer	0.0408	0.157	CbGeAlD
Trametinib—MAP2K1—brainstem—pharynx cancer	0.0311	0.12	CbGeAlD
Trametinib—CYP3A4—Fatty Acid Omega Oxidation—ADH7—pharynx cancer	0.0284	0.0384	CbGpPWpGaD
Trametinib—MAP2K2—saliva-secreting gland—pharynx cancer	0.028	0.108	CbGeAlD
Trametinib—MAP2K1—epithelium—pharynx cancer	0.0277	0.107	CbGeAlD
Trametinib—CYP3A4—Fatty Acid Omega Oxidation—ADH1B—pharynx cancer	0.0249	0.0336	CbGpPWpGaD
Trametinib—MAP2K1—lymphoid tissue—pharynx cancer	0.0214	0.0824	CbGeAlD
Trametinib—MAP2K1—spinal cord—pharynx cancer	0.0194	0.0747	CbGeAlD
Trametinib—MAP2K2—lymphoid tissue—pharynx cancer	0.0188	0.0725	CbGeAlD
Trametinib—MAP2K1—head—pharynx cancer	0.0172	0.0664	CbGeAlD
Trametinib—MAP2K2—spinal cord—pharynx cancer	0.0171	0.0658	CbGeAlD
Trametinib—MAP2K2—Bladder Cancer—CDH1—pharynx cancer	0.0169	0.0229	CbGpPWpGaD
Trametinib—MAP2K1—Bladder Cancer—CDH1—pharynx cancer	0.0158	0.0214	CbGpPWpGaD
Trametinib—MAP2K1—BCR signaling pathway—CD79A—pharynx cancer	0.0154	0.0207	CbGpPWpGaD
Trametinib—MAP2K2—head—pharynx cancer	0.0152	0.0584	CbGeAlD
Trametinib—MAP2K2—IL-7 Signaling Pathway—CCND1—pharynx cancer	0.015	0.0202	CbGpPWpGaD
Trametinib—CYP2C8—Phase 1 - Functionalization of compounds—ADH7—pharynx cancer	0.0149	0.0201	CbGpPWpGaD
Trametinib—MAP2K1—IL-7 Signaling Pathway—CCND1—pharynx cancer	0.014	0.0189	CbGpPWpGaD
Trametinib—MAP2K2—Signal transduction by L1—EGFR—pharynx cancer	0.0135	0.0183	CbGpPWpGaD
Trametinib—MAP2K2—GRB2 events in EGFR signaling—EGFR—pharynx cancer	0.0135	0.0183	CbGpPWpGaD
Trametinib—CYP2C8—Phase 1 - Functionalization of compounds—ADH1B—pharynx cancer	0.0131	0.0176	CbGpPWpGaD
Trametinib—MAP2K2—SHC1 events in EGFR signaling—EGFR—pharynx cancer	0.013	0.0176	CbGpPWpGaD
Trametinib—MAP2K1—GRB2 events in EGFR signaling—EGFR—pharynx cancer	0.0127	0.0171	CbGpPWpGaD
Trametinib—MAP2K1—Signal transduction by L1—EGFR—pharynx cancer	0.0127	0.0171	CbGpPWpGaD
Trametinib—MAP2K2—Bladder Cancer—CCND1—pharynx cancer	0.0126	0.017	CbGpPWpGaD
Trametinib—MAP2K2—B Cell Receptor Signaling Pathway—CD79A—pharynx cancer	0.0122	0.0165	CbGpPWpGaD
Trametinib—MAP2K1—SHC1 events in EGFR signaling—EGFR—pharynx cancer	0.0122	0.0165	CbGpPWpGaD
Trametinib—MAP2K1—lymph node—pharynx cancer	0.0121	0.0465	CbGeAlD
Trametinib—MAP2K1—Bladder Cancer—CCND1—pharynx cancer	0.0118	0.0159	CbGpPWpGaD
Trametinib—MAP2K1—B Cell Receptor Signaling Pathway—CD79A—pharynx cancer	0.0114	0.0154	CbGpPWpGaD
Trametinib—MAP2K2—Nanoparticle-mediated activation of receptor signaling—EGFR—pharynx cancer	0.0107	0.0145	CbGpPWpGaD
Trametinib—MAP2K2—lymph node—pharynx cancer	0.0106	0.0409	CbGeAlD
Trametinib—MAP2K2—GRB2 events in ERBB2 signaling—EGFR—pharynx cancer	0.0102	0.0137	CbGpPWpGaD
Trametinib—MAP2K1—Nanoparticle-mediated activation of receptor signaling—EGFR—pharynx cancer	0.0101	0.0136	CbGpPWpGaD
Trametinib—MAP2K2—Bladder Cancer—EGFR—pharynx cancer	0.00991	0.0134	CbGpPWpGaD
Trametinib—MAP2K2—SHC1 events in ERBB2 signaling—EGFR—pharynx cancer	0.00966	0.013	CbGpPWpGaD
Trametinib—MAP2K1—GRB2 events in ERBB2 signaling—EGFR—pharynx cancer	0.00951	0.0128	CbGpPWpGaD
Trametinib—MAP2K1—Bladder Cancer—EGFR—pharynx cancer	0.00927	0.0125	CbGpPWpGaD
Trametinib—MAP2K1—FOXM1 transcription factor network—CCND1—pharynx cancer	0.00927	0.0125	CbGpPWpGaD
Trametinib—MAP2K1—SHC1 events in ERBB2 signaling—EGFR—pharynx cancer	0.00904	0.0122	CbGpPWpGaD
Trametinib—CYP2C8—Biological oxidations—CNDP2—pharynx cancer	0.00875	0.0118	CbGpPWpGaD
Trametinib—MAP2K2—Bladder Cancer—TP53—pharynx cancer	0.00832	0.0112	CbGpPWpGaD
Trametinib—CYP3A4—Phase 1 - Functionalization of compounds—ADH7—pharynx cancer	0.008	0.0108	CbGpPWpGaD
Trametinib—MAP2K2—Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met)—CDH1—pharynx cancer	0.00793	0.0107	CbGpPWpGaD
Trametinib—CYP2C8—Biological oxidations—ADH7—pharynx cancer	0.00792	0.0107	CbGpPWpGaD
Trametinib—MAP2K1—Bladder Cancer—TP53—pharynx cancer	0.00778	0.0105	CbGpPWpGaD
Trametinib—MAP2K1—ErbB Signaling Pathway—CCND1—pharynx cancer	0.00758	0.0102	CbGpPWpGaD
Trametinib—MAP2K1—Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met)—CDH1—pharynx cancer	0.00742	0.01	CbGpPWpGaD
Trametinib—MAP2K2—Amyotrophic lateral sclerosis (ALS)—TP53—pharynx cancer	0.00707	0.00954	CbGpPWpGaD
Trametinib—CYP3A4—Phase 1 - Functionalization of compounds—ADH1B—pharynx cancer	0.00701	0.00947	CbGpPWpGaD
Trametinib—CYP2C8—Biological oxidations—ADH1B—pharynx cancer	0.00694	0.00937	CbGpPWpGaD
Trametinib—MAP2K1—Signaling events mediated by focal adhesion kinase—CCND1—pharynx cancer	0.00687	0.00928	CbGpPWpGaD
Trametinib—MAP2K1—Neurotrophic factor-mediated Trk receptor signaling—CCND1—pharynx cancer	0.00687	0.00928	CbGpPWpGaD
Trametinib—MAP2K1—Aryl Hydrocarbon Receptor—EGFR—pharynx cancer	0.00676	0.00913	CbGpPWpGaD
Trametinib—MAP2K2—Leptin signaling pathway—CCND1—pharynx cancer	0.00623	0.00841	CbGpPWpGaD
Trametinib—MAP2K2—SHP2 signaling—EGFR—pharynx cancer	0.006	0.0081	CbGpPWpGaD
Trametinib—MAP2K1—ErbB Signaling Pathway—EGFR—pharynx cancer	0.00595	0.00803	CbGpPWpGaD
Trametinib—MAP2K1—Leptin signaling pathway—CCND1—pharynx cancer	0.00583	0.00787	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways in Glioblastoma—CCND1—pharynx cancer	0.0058	0.00783	CbGpPWpGaD
Trametinib—MAP2K1—SHP2 signaling—EGFR—pharynx cancer	0.00562	0.00758	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways in Glioblastoma—CCND1—pharynx cancer	0.00543	0.00732	CbGpPWpGaD
Trametinib—MAP2K1—AGE/RAGE pathway—EGFR—pharynx cancer	0.00506	0.00684	CbGpPWpGaD
Trametinib—MAP2K1—ErbB Signaling Pathway—TP53—pharynx cancer	0.00499	0.00674	CbGpPWpGaD
Trametinib—CYP3A4—Biological oxidations—CNDP2—pharynx cancer	0.0047	0.00634	CbGpPWpGaD
Trametinib—MAP2K2—Oncostatin M Signaling Pathway—TP53—pharynx cancer	0.0046	0.00621	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways in Glioblastoma—EGFR—pharynx cancer	0.00455	0.00614	CbGpPWpGaD
Trametinib—MAP2K1—Oncostatin M Signaling Pathway—TP53—pharynx cancer	0.0043	0.00581	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways in Glioblastoma—EGFR—pharynx cancer	0.00426	0.00575	CbGpPWpGaD
Trametinib—CYP3A4—Biological oxidations—ADH7—pharynx cancer	0.00425	0.00574	CbGpPWpGaD
Trametinib—MAP2K2—L1CAM interactions—EGFR—pharynx cancer	0.00401	0.00541	CbGpPWpGaD
Trametinib—MAP2K2—TGF-beta Signaling Pathway—CCND1—pharynx cancer	0.00396	0.00535	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways in Glioblastoma—TP53—pharynx cancer	0.00382	0.00516	CbGpPWpGaD
Trametinib—MAP2K1—L1CAM interactions—EGFR—pharynx cancer	0.00375	0.00507	CbGpPWpGaD
Trametinib—MAP2K2—ErbB1 downstream signaling—EGFR—pharynx cancer	0.00373	0.00504	CbGpPWpGaD
Trametinib—CYP3A4—Biological oxidations—ADH1B—pharynx cancer	0.00373	0.00503	CbGpPWpGaD
Trametinib—MAP2K1—TGF-beta Signaling Pathway—CCND1—pharynx cancer	0.00371	0.005	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways in Glioblastoma—TP53—pharynx cancer	0.00357	0.00482	CbGpPWpGaD
Trametinib—MAP2K1—ErbB1 downstream signaling—EGFR—pharynx cancer	0.00349	0.00472	CbGpPWpGaD
Trametinib—MAP2K2—Focal Adhesion—CCND1—pharynx cancer	0.00296	0.004	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by SCF-KIT—EGFR—pharynx cancer	0.00295	0.00398	CbGpPWpGaD
Trametinib—MAP2K1—Senescence and Autophagy in Cancer—TP53—pharynx cancer	0.00293	0.00396	CbGpPWpGaD
Trametinib—MAP2K2—Disease—B4GALT5—pharynx cancer	0.00288	0.00388	CbGpPWpGaD
Trametinib—MAP2K2—Regulation of Actin Cytoskeleton—EGFR—pharynx cancer	0.00282	0.00381	CbGpPWpGaD
Trametinib—MAP2K2—Downstream signaling of activated FGFR—EGFR—pharynx cancer	0.00282	0.00381	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by ERBB4—EGFR—pharynx cancer	0.00278	0.00375	CbGpPWpGaD
Trametinib—MAP2K1—Focal Adhesion—CCND1—pharynx cancer	0.00277	0.00374	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by SCF-KIT—EGFR—pharynx cancer	0.00276	0.00372	CbGpPWpGaD
Trametinib—MAP2K1—Integrated Pancreatic Cancer Pathway—CCND1—pharynx cancer	0.00276	0.00372	CbGpPWpGaD
Trametinib—MAP2K1—Disease—B4GALT5—pharynx cancer	0.00269	0.00363	CbGpPWpGaD
Trametinib—MAP2K2—Downstream signal transduction—EGFR—pharynx cancer	0.00265	0.00358	CbGpPWpGaD
Trametinib—MAP2K1—Regulation of Actin Cytoskeleton—EGFR—pharynx cancer	0.00264	0.00356	CbGpPWpGaD
Trametinib—MAP2K1—Downstream signaling of activated FGFR—EGFR—pharynx cancer	0.00264	0.00356	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by FGFR—EGFR—pharynx cancer	0.00264	0.00356	CbGpPWpGaD
Trametinib—MAP2K2—EGF/EGFR Signaling Pathway—EGFR—pharynx cancer	0.00264	0.00356	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by ERBB2—EGFR—pharynx cancer	0.00263	0.00354	CbGpPWpGaD
Trametinib—MAP2K2—DAP12 signaling—EGFR—pharynx cancer	0.00261	0.00353	CbGpPWpGaD
Trametinib—MAP2K2—TGF-beta Signaling Pathway—TP53—pharynx cancer	0.00261	0.00352	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by ERBB4—EGFR—pharynx cancer	0.0026	0.00351	CbGpPWpGaD
Trametinib—MAP2K2—MAPK Signaling Pathway—EGFR—pharynx cancer	0.00256	0.00346	CbGpPWpGaD
Trametinib—MAP2K1—Downstream signal transduction—EGFR—pharynx cancer	0.00248	0.00335	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by FGFR—EGFR—pharynx cancer	0.00247	0.00333	CbGpPWpGaD
Trametinib—MAP2K1—EGF/EGFR Signaling Pathway—EGFR—pharynx cancer	0.00247	0.00333	CbGpPWpGaD
Trametinib—MAP2K2—DAP12 interactions—EGFR—pharynx cancer	0.00246	0.00332	CbGpPWpGaD
Trametinib—MAP2K2—Fc epsilon receptor (FCERI) signaling—EGFR—pharynx cancer	0.00246	0.00332	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by FGFR in disease—EGFR—pharynx cancer	0.00246	0.00332	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by ERBB2—EGFR—pharynx cancer	0.00246	0.00332	CbGpPWpGaD
Trametinib—MAP2K1—DAP12 signaling—EGFR—pharynx cancer	0.00244	0.0033	CbGpPWpGaD
Trametinib—MAP2K1—TGF-beta Signaling Pathway—TP53—pharynx cancer	0.00244	0.0033	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by EGFR—EGFR—pharynx cancer	0.00244	0.00329	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by EGFR in Cancer—EGFR—pharynx cancer	0.00241	0.00326	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by PDGF—EGFR—pharynx cancer	0.0024	0.00325	CbGpPWpGaD
Trametinib—MAP2K1—MAPK Signaling Pathway—EGFR—pharynx cancer	0.0024	0.00324	CbGpPWpGaD
Trametinib—MAP2K2—Focal Adhesion—EGFR—pharynx cancer	0.00232	0.00314	CbGpPWpGaD
Trametinib—MAP2K1—DAP12 interactions—EGFR—pharynx cancer	0.0023	0.00311	CbGpPWpGaD
Trametinib—MAP2K1—Fc epsilon receptor (FCERI) signaling—EGFR—pharynx cancer	0.0023	0.00311	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by FGFR in disease—EGFR—pharynx cancer	0.0023	0.00311	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by EGFR—EGFR—pharynx cancer	0.00228	0.00308	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by EGFR in Cancer—EGFR—pharynx cancer	0.00226	0.00305	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by PDGF—EGFR—pharynx cancer	0.00225	0.00304	CbGpPWpGaD
Trametinib—MAP2K2—NGF signalling via TRKA from the plasma membrane—EGFR—pharynx cancer	0.00218	0.00294	CbGpPWpGaD
Trametinib—MAP2K1—Focal Adhesion—EGFR—pharynx cancer	0.00217	0.00293	CbGpPWpGaD
Trametinib—MAP2K1—Integrated Pancreatic Cancer Pathway—EGFR—pharynx cancer	0.00216	0.00292	CbGpPWpGaD
Trametinib—MAP2K2—MAPK Signaling Pathway—TP53—pharynx cancer	0.00215	0.00291	CbGpPWpGaD
Trametinib—MAP2K2—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—pharynx cancer	0.0021	0.00284	CbGpPWpGaD
Trametinib—MAP2K1—NGF signalling via TRKA from the plasma membrane—EGFR—pharynx cancer	0.00204	0.00275	CbGpPWpGaD
Trametinib—MAP2K1—MAPK Signaling Pathway—TP53—pharynx cancer	0.00201	0.00272	CbGpPWpGaD
Trametinib—MAP2K1—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—pharynx cancer	0.00197	0.00266	CbGpPWpGaD
Trametinib—MAP2K1—Integrated Pancreatic Cancer Pathway—TP53—pharynx cancer	0.00182	0.00245	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—CD79A—pharynx cancer	0.00171	0.00231	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by NGF—EGFR—pharynx cancer	0.00167	0.00226	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—CD79A—pharynx cancer	0.0016	0.00216	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by NGF—EGFR—pharynx cancer	0.00157	0.00212	CbGpPWpGaD
Trametinib—MAP2K2—Axon guidance—EGFR—pharynx cancer	0.00152	0.00205	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—CNDP2—pharynx cancer	0.0015	0.00202	CbGpPWpGaD
Trametinib—MAP2K1—Axon guidance—EGFR—pharynx cancer	0.00142	0.00191	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—ADH7—pharynx cancer	0.00135	0.00183	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—ADH1B—pharynx cancer	0.00119	0.0016	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—B4GALT5—pharynx cancer	0.00113	0.00153	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—EGFR—pharynx cancer	0.00108	0.00146	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—EGFR—pharynx cancer	0.00101	0.00137	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—EGFR—pharynx cancer	0.000955	0.00129	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—CDH1—pharynx cancer	0.000951	0.00128	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—EGFR—pharynx cancer	0.000894	0.00121	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—CDH1—pharynx cancer	0.00089	0.0012	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—CNDP2—pharynx cancer	0.000804	0.00108	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—ADH7—pharynx cancer	0.000727	0.000981	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—ADH1B—pharynx cancer	0.000637	0.00086	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—B4GALT5—pharynx cancer	0.000609	0.000822	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—EGFR—pharynx cancer	0.000609	0.000822	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—EGFR—pharynx cancer	0.00057	0.000769	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—EGFR—pharynx cancer	0.000556	0.000751	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—EGFR—pharynx cancer	0.00052	0.000703	CbGpPWpGaD
Trametinib—MAP2K2—Disease—EGFR—pharynx cancer	0.000514	0.000693	CbGpPWpGaD
Trametinib—MAP2K1—Disease—EGFR—pharynx cancer	0.000481	0.000649	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—CCND1—pharynx cancer	0.000458	0.000619	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—CCND1—pharynx cancer	0.000429	0.000579	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—EGFR—pharynx cancer	0.00036	0.000486	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—EGFR—pharynx cancer	0.000337	0.000454	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—TP53—pharynx cancer	0.000302	0.000408	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—TP53—pharynx cancer	0.000283	0.000381	CbGpPWpGaD
